• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Acutus Medical Inc.

    4/25/24 4:07:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AFIB alert in real time by email
    DEFA14A 1 d74523ddefa14a.htm DEFA14A DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under § 240.14a-12

     

    LOGO

    Acutus Medical, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required.

     

    ☐

    Fee previously paid with preliminary materials.

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     


    LOGO

    C/O TABULATOR, P.O. BOX 8016, CARY, NC 27512-9903
    Your vote
    matters!
    Acutus Medical, Inc.
    Annual Meeting of Stockholders
    Thursday, June 13, 2024 8:00 AM, Pacific Time
    Annual Meeting will be held via live video webcast. Please visit www.proxydocs.com/AFIB for
    more details.
    You must register to attend the meeting online and/or participate at
    www.proxydocs.com/AFIB
    For a convenient way to view proxy materials, VOTE, and obtain
    directions to attend the meeting go to www.proxydocs.com/AFIB
    To vote your proxy while visiting this site, you will need the 12 digit
    control number in the box below.
    This communication presents only an overview of the more complete proxy materials that are
    available to you on the Internet. This is not a ballot. You cannot use this notice to vote your
    shares. We encourage you to access and review all of the important information contained in
    the proxy materials before voting.
    Under United States Securities and Exchange Commission rules, proxy materials do not have
    to be delivered in paper. Proxy materials can be distributed by making them available on the
    internet.
    If you want to receive a paper or e-mail copy of the proxy material, you must request one.
    There is no charge to you for requesting a copy. In order to receive a paper package in time
    for this year’s meeting, you must make this request on or before June 3, 2024.
    styleINA
    C/O TABULATOR, P.O. BOX 8016, CARY, NC 27512-9903
    SEE REVERSE FOR FULL AGENDA
    Scan QR for digital voting
    Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K
    Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 13, 2024 For Stockholders of record as of April 15, 2024
    To order paper materials, use one of the following methods.
    Internet: www.investorelections.com/AFIB
    Call:
    1-866-648-8133
    Email: [email protected]
    * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.
    Your control number
    Have the 12 digit control number located in the box above available when you access the website and follow the instructions.
    Copyright © 2024 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO

    Acutus Medical, Inc. Annual Meeting of Stockholders
    THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2
    PROPOSAL
    1. To elect the two nominees for Class I director to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified;
    1.01 John Sheridan
    1.02 Niamh Pellegrini
    2. To ratify the selection of KPMG LLP as the independent registered public accounting firm for Acutus for the fiscal year ending December 31, 2024; and
    3. To conduct any other business properly brought before the Annual Meeting.

    Get the next $AFIB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AFIB

    DatePrice TargetRatingAnalyst
    1/20/2022Buy → Neutral
    BTIG
    1/14/2022$10.00 → $3.00Buy → Hold
    Canaccord Genuity
    11/15/2021Neutral → Underweight
    JP Morgan
    11/12/2021Neutral → Underweight
    JP Morgan
    11/12/2021$18.00 → $10.00Buy
    Canaccord Genuity
    10/22/2021$10.00Neutral
    Goldman
    7/15/2021$11.00 → $18.00Hold → Buy
    Canaccord Genuity
    More analyst ratings

    $AFIB
    SEC Filings

    View All

    SEC Form 10-K filed by Acutus Medical Inc.

    10-K - Acutus Medical, Inc. (0001522860) (Filer)

    3/24/25 5:27:27 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Acutus Medical, Inc. (0001522860) (Filer)

    3/24/25 4:07:31 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Acutus Medical Inc.

    SCHEDULE 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    1/28/25 5:40:03 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director by deputization Flynn James E

    4 - Acutus Medical, Inc. (0001522860) (Issuer)

    1/28/25 9:00:08 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Mukai Takeo covered exercise/tax liability with 8,475 units of Form 4, decreasing direct ownership by 10% to 72,874 units (SEC Form 4)

    4 - Acutus Medical, Inc. (0001522860) (Issuer)

    3/4/24 5:20:05 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Sohn Tom covered exercise/tax liability with 7,582 units of Form 4, decreasing direct ownership by 7% to 105,009 units (SEC Form 4)

    4 - Acutus Medical, Inc. (0001522860) (Issuer)

    2/7/24 4:12:59 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Acutus Medical Reports Full Year 2024 Financial Results

    CARLSBAD, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the full year of 2024. Recent Highlights: 2024 Revenue from Continuing Operations of $20.2 million grew 181% year-over-year, from $7.2 million last year.Operating loss for continuing operations was $0.1 million, compared to 11.7 million last year.Recorded $10.8 million in gain on sale of business, an increase of 19% compared to last year.Cash, cash equivalents, marketable securities and restricted cash were $14.0 million as of December 31, 2024. Full Year 2024 Financial ResultsRevenue from Continuing Operations was $20.2 million for 2024, an increas

    3/24/25 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Announces Operational Downsizing

    CARLSBAD, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced a realignment of resources and operational downsizing. Dr. Shaden Marzouk, Chairperson of the Board of Directors of Acutus, commented, "Following an extensive strategic review by the Company's Board of Directors, we are taking the hard but necessary steps to reduce the size of our organization while complying with our remaining obligations to Medtronic for the production of left-heart access products." Takeo Mukai, CEO & CFO of Acutus, added, "The operational downsizing impacts our team, and it is difficult to part with our valued and highly talented colleag

    12/4/24 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results

    CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the third quarter and year-to-date of 2024. Recent Highlights: Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.Recorded $2.4 million in gain on sale of business, a decrease of 8% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $12.6 million as of September 30, 2024. Thi

    11/14/24 4:26:42 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Acutus Medical downgraded by BTIG

    BTIG downgraded Acutus Medical from Buy to Neutral

    1/20/22 9:29:42 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Acutus Medical from Buy to Hold and set a new price target of $3.00 from $10.00 previously

    1/14/22 8:31:41 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical downgraded by JP Morgan

    JP Morgan downgraded Acutus Medical from Neutral to Underweight

    11/15/21 7:17:46 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Leadership Updates

    Live Leadership Updates

    View All

    Acutus Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Results and Appointment of Chief Financial Officer

    CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the fourth quarter and full year 2022. The Company also announced the appointment of Takeo Mukai as Senior Vice President & Chief Financial Officer. Preliminary Unaudited Fourth Quarter and Full Year 2022 ResultsThe Company expects fourth quarter 2022 revenue of approximately $4.7-$4.9 million compared to $4.4 million in the fourth quarter of 2021. Year-over-year growth was driven by an increase in commercial AcQMap pr

    1/9/23 6:00:00 AM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    BrightInsight Adds Medical Device and Biopharmaceutical Experts, Tamara Elias, M.D., and Scott Huennekens to Advisory Council

    SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek

    9/7/22 8:30:00 AM ET
    $AFIB
    $AVGR
    $HYPR
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments

    Acutus Medical Appoints Niamh Pellegrini to Board of Directors

    CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Niamh Pellegrini to the Company's Board of Directors, effective August 10, 2021. Ms. Pellegrini has over 20 years of experience in the healthcare industry and, since July 2019, has served as the Chief Commercial Officer of Nevro, Inc., a medical device company dedicated to helping patients suffering from chronic pain achieve lasting relief. "Niamh is an experienced and proven executive and commercial leader," said Vince Burgess, President and CEO of Acutu

    8/12/21 4:02:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Financials

    Live finance-specific insights

    View All

    Acutus Medical to Cancel Third Quarter 2023 Conference Call

    CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023. About Acutus Medical, Inc.Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California. Investor Contact:Chad HollisterAcutus

    11/10/23 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical to Announce Third Quarter 2023 Financial Results

    CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a

    11/2/23 4:13:07 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Acutus Medical Reports Second Quarter 2023 Financial Results

    CARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023. Recent Highlights: Second quarter revenue of $5.3 million grew 30% year-over-year, reflecting strong procedure volume growth and improved capital salesQuarterly AcQMap procedure volumes set a new record and increased 21% compared to the second quarter of 2022Received FDA 510K clearance for AcQMap 9 next generation software platform featuring advanced algorithms and automation to improve diagnostic capabil

    8/7/23 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $AFIB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13G/A filed by Acutus Medical Inc.

    SC 13G/A - Acutus Medical, Inc. (0001522860) (Subject)

    11/14/24 1:03:20 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Acutus Medical Inc.

    SC 13G - Acutus Medical, Inc. (0001522860) (Subject)

    5/17/24 5:20:26 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care